Homing of chloromethylbenzoyl ammonia-labeled bone marrow mesenchymal stem cells in an immune-mediated bone marrow failure mouse model in vivo.

Aplastic anemia is an abnormal immune reaction disease in which T lymphocytes destroy hematopoietic stem and progenitor cells because of immune hyperactivity. Bone marrow mesenchymal stem cells (BMSCs) have hematopoietic supporting and immune regulation functions. This study investigated BMSCs homing in mice transplantation models after bone marrow failure. BALB/c mice were randomly divided into three groups: normal control, bone marrow failure model, and BMSC transplantation group. Chloromethyl benzamido-labeled BMSCs of BALB/c mice were transplanted through tail vein injection in mouse models with bone marrow failure. Flow cytometry and histological fluorescence microscopy were used to observe the dynamic distribution of labeled cells in different tissues. Average survival time, peripheral blood, and bone marrow morphological features were observed in mice from each group. Twenty-four hours after tail vein infusion of BMSCs, positively labeled cells were observed in the bone marrows of recipient mice, and the number of positive cells increased significantly at 72 h (P < 0.05). In dead or dying mice, white blood cells, hemoglobin, platelets, and bone marrow mononuclear cells were all significantly higher in the BMSC transplantation group than in the BMSCs of the model group (P < 0.01). Mean survival time was significantly shorter in the bone marrow failure model group than in the transplantation group (P < 0.05). These results confirmed that the major of BMSCs injected via tail vein could migrate to injured bone marrow tissues within 24-72 h in a mouse model of bone marrow failure. Furthermore, BMSCs can promote hematopoietic recovery, reduce the degree of bone marrow failure, and significantly prolong survival time.

Transplante de médula ósea de trilliza idéntica a paciente con hemoglobinuria paroxística nocturna (HPN) y anemia aplástica / Transplantation of bone marrow from triplet of patient with paroxysmal nocturnal hemoglobin (PNH) and aplastic anemia

Una paciente con hemoglobinuria paroxística nocturna y aplasia severa de la médula ósea fue tratada con transplante de la médula ósea de su hermana trilliza idéntica. La paciente fue preparada con ciclofosfamida y ha tenido recuperación medular completa y constante. Las pruebas que identifican la hemoglobinuria paroxística nocturna han sido persistentemente negativas. La paciente ha estado clínica y hematológicamente normal durante más de 8 años sin ninguna medicación